C2 rs11693222: Understanding Complement System Variants
The rs11693222 variant is a genetic polymorphism located within the C2 gene, which encodes a protein essential for the body's immune complement system. Research has investigated this variant for its potential role in modifying complement cascade activation, particularly in the context of chorioretinal tissues and age-related macular degeneration.
What each genotype means
Typical complement activity
This genotype represents the most common genetic configuration at this position in many populations. Research suggests this variant may influence complement cascade activation in chorioretinal tissues, though the clinical significance of this specific genotype remains limited and requires further study.
Carried by the majority of individuals in European populations, where the minor allele frequency is approximately 0.07.
Modified complement activity
Carrying one copy of the minor allele may be associated with subtle differences in how the complement system functions in certain tissues. Because the evidence linking this variant to specific health outcomes is limited, it is unclear how this genotype influences individual disease risk.
Carried by roughly 1 in 7 to 1 in 8 people of European ancestry.
Potential complement activity variation
This genotype is the least common configuration for this variant. While some studies suggest that variations in the C2 gene can modify complement activation, the clinical impact of this specific genotype is not well-established and should not be used to predict health outcomes.
This genotype is rare, occurring in less than 1% of individuals in European populations.
What is rs11693222?
The rs11693222 variant is a single nucleotide polymorphism (SNP) situated within the C2 gene on chromosome 6. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. The C2 gene is located in the major histocompatibility complex (MHC) class III region, a highly dense area of the genome involved in immune regulation. Because this region contains multiple genes that are often inherited together as a block, or haplotype, researchers frequently study rs11693222 alongside neighboring genes like complement factor B (CFB). This proximity means that the variant is often in strong linkage disequilibrium with other nearby genetic markers, making it important to consider the broader genetic context when interpreting its potential biological impact.
The Role of the C2 Gene
The C2 gene provides instructions for making the complement C2 protein, a serum glycoprotein that serves as a critical component of the classical pathway of the complement system. The complement system is a part of the innate immune system that helps the body clear pathogens and damaged cells. When the system is activated, C2 is cleaved into two fragments, C2a and C2b. The C2a fragment acts as a serine proteinase, combining with complement factor 4b to form the C3 or C5 convertase. These convertases are essential for the downstream activation of the complement cascade, which leads to inflammation and the destruction of target cells. Because of its central role in immune surveillance, variations in C2 can theoretically influence the intensity or regulation of the inflammatory response in various tissues, including the eye.
Research and Evidence Strength
Scientific interest in rs11693222 stems from its location in a gene cluster associated with age-related macular degeneration (AMD). While the complement system is known to be a major driver of AMD risk, the evidence specifically linking rs11693222 to clinical outcomes remains limited. Some studies have identified haplotypes spanning the C2 and CFB genes that correlate with a decreased risk of developing AMD, but isolating the functional effect of this specific SNP is challenging due to the complex genetic architecture of the region. Current research suggests that while complement pathway variants collectively account for a significant portion of AMD genetic risk, the individual contribution of rs11693222 is not fully established. It is important to note that genetic associations are statistical in nature and do not imply a direct cause-and-effect relationship for any individual.
Population Frequency
The rs11693222 variant is observed across various global populations, with a minor allele frequency of approximately 0.07 in European populations. This frequency indicates that the variant is relatively common, though it is not the majority allele in these groups. Because allele frequencies can vary significantly between different ancestral backgrounds, researchers often look at large-scale genomic databases to understand how common a variant is across diverse populations. Understanding these frequencies is a standard part of genomic research, as it helps scientists determine whether a variant is rare or common and provides context for its potential role in population-specific disease risk. As with many variants in the MHC region, the distribution of rs11693222 may reflect historical evolutionary pressures related to immune function.
Interpreting Genetic Information
Genetic information regarding variants like rs11693222 is intended for educational purposes and should not be used for medical diagnosis or to guide personal health decisions. The presence of a specific genotype does not guarantee the development of any condition, nor does it provide a definitive prediction of health outcomes. Many factors, including environment, lifestyle, and the interaction of thousands of other genes, contribute to complex traits like eye health. If you are concerned about your risk for age-related macular degeneration or other conditions, the most appropriate step is to consult with an eye care professional or a genetic counselor. They can provide a comprehensive assessment based on your personal and family medical history, which is far more informative than any single genetic variant.
How common is this variant?
The minor allele frequency for rs11693222 is approximately 0.07 in European populations, making it a relatively common variant.
Frequently asked questions
Does having the rs11693222 variant mean I will get AMD?
No. Genetic variants are statistical markers associated with risk, not diagnostic tools. Many people with this variant never develop AMD, and many people without it do.
Can I change my risk associated with this SNP?
Genetic variants themselves cannot be changed. However, you can focus on modifiable lifestyle factors known to support eye health, such as maintaining a healthy diet, not smoking, and getting regular eye exams.
Is rs11693222 the only gene involved in AMD?
No. AMD is a complex, polygenic condition involving many genes, including CFH, C3, and ARMS2. It is the result of the interaction between many genetic factors and environmental influences.
Should I get a genetic test for this variant?
Routine genetic testing for individual AMD-associated SNPs is generally not recommended for the general public. Clinical decisions are best made based on comprehensive eye exams and family history.
Sources & further reading
Educational information only, last refreshed 9/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11693222?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29